Previous 10 | Next 10 |
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that it will host a Research & Development (R&...
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a panel presentat...
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in two upcoming inves...
2023-08-04 17:35:56 ET Gainers: Atara Biotherapeutics ( ATRA ) +5% . NGM Biopharmaceuticals ( NGM ) +5% . Galera Therapeutics ( GRTX ) +4% . Ovid Therapeutics ( OVID ) +3% . Magnite ( MGNI ) +3% . Losers: Applied Material...
2023-08-04 12:26:04 ET Ovid Therapeutics press release ( NASDAQ: OVID ): Q2 GAAP EPS of -$0.18 beats by $0.03 . Revenue was $75,000 for the three months ended June 30, 2023, as compared to no revenue recognized in the same period of 2022. Total operating expen...
Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment and initiated collaboration with Graviton Bioscience to develop highly selective ROCK2 inhibitors for rare neurological c...
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will participate in a fireside chat at...
2023-07-05 10:00:00 ET Summary We've compiled a list of June Investment Picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. The investment ideas featured h...
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude Nicaise Meg Alexander promoted to Chief Strategy Officer Ovid streamlined G&A infrastructure to improve oper...
2023-06-26 08:31:53 ET Ovid Therapeutics ( NASDAQ: OVID ) has announced that the Co. was added to the Russell 3000 Index, effective after the U.S. market opens on June 26, 2023. “Increased exposure through this Index enables prospective investors to take part in the...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...